CClinicalTrials.gg
RecruitingNCT07176273ADAPT-PTSDUpdated Dec 19, 2025

Adaptive Decision-making And Personalized Treatment for PTSD (ADAPT-PTSD)

An interventional study of Modular Cognitive Processing Therapy and Modular Prolonged Exposure Therapy in Posttraumatic Stress Disorder and PTSD, sponsored by The University of Texas Health Science Center at San Antonio. Recruiting at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-19.

Sponsored by The University of Texas Health Science Center at San Antonio · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2025; still recruiting 9 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
302
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

By doing this research project, the investigators hope to learn which strategies work best to help veterans who are not benefiting from their first PTSD treatment or not completing between-session homework assignments regularly that might improve treatment response. The investigators also want to learn how best to match the right type and amount of treatment to each individual veteran. By conducting this research project, they hope to:

  • See if trying a different treatment strategy for veterans not responding to their first PTSD treatment would be more helpful
  • See if sending text message prompts between sessions encourages more completion of between-session homework
Read the detailed description

This study is designed to assist the investigators in answering the clinical question of how to address non-response to first line PTSD treatments. Utilizing an innovative Hybrid Experimental Design (HED), the proposed study involves multiple, sequential randomizations to both therapist-delivered and digital interventions operating on short and long timescales to determine the optimal combination and sequencing of evidence-based interventions to maximize response. This will result in actionable data and, consistent with a personalized medicine approach, an implementable, adaptive treatment regimen that optimizes clinical resource allocation. By recruiting and providing treatment in routine care settings serving veterans with PTSD, the study design maximizes generalizability, relevance to the VA mission, and implementation potential.

02

Conditions studied

  • Posttraumatic Stress Disorder
  • PTSD

Keywords

  • Veterans
03

In context

Stress Disorders, Post-Traumatic

2,239 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 554 are open to participants now.

This study's planned enrollment of 302 is above the median of 70 across 1,858 interventional studies indexed under Stress Disorders, Post-Traumatic.

Browse Stress Disorders, Post-Traumatic studies →

Lead sponsor

The University of Texas Health Science Center at San Antonio is the lead sponsor of 435 studies on the registry; 88 are open to participants now.

Of its 62 completed or terminated interventional studies of FDA-regulated products, 31 (50%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Veterans eligible for PE and CPT at the participating PTSD treatment-providing clinic who are
  2. At least 18 years or older
  3. Score ≥ 31 on the PCL-5 secondary to a Criterion A traumatic event
  4. Own a mobile device that can be used for the therapy companion mobile app (Prolonged Exposure (PE) coach or Cognitive Processing Therapy (CPT) coach).

Exclusion criteria

Exclusion Criteria:

  1. Acute suicide risk requiring clinical intervention
  2. Need for detoxification
  3. Unmanaged psychosis or bipolar disorder
  4. Severe cognitive impairment that makes it unlikely that participants can adhere to the study regimen (as evidenced by confusion, inability to track discussion or answer questions, or other clear and significant indicators of cognitive impairment)
  5. Current or past 12-month engagement in PE or CPT.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
302 participants (estimated)

Study arms

  • Active comparator
    Early CPT Non-Responders Switch (Group A)

    Early NON-RESPONDERS to CPT will SWITCH to PE

    Behavioral: Digital Interventions · Behavioral: Cognitive Processing Therapy (CPT) · Behavioral: Prolonged Exposure (PE)

  • Active comparator
    Early CPT Non-Responders Modular (Group B)

    Early NON-RESPONDERS to CPT will transition to MODULAR CPT

    Behavioral: Modular Cognitive Processing Therapy · Behavioral: Digital Interventions · Behavioral: Cognitive Processing Therapy (CPT)

  • Active comparator
    Early CPT Responders Continue (Group C)

    Early RESPONDERS to CPT will CONTINUE in their CPT treatment

    Behavioral: Digital Interventions · Behavioral: Cognitive Processing Therapy (CPT)

  • Active comparator
    Early CPT Responders Step Down (Group D)

    Early RESPONDERS to CPT will STEP DOWN to self-managed CPT

    Behavioral: Step Down Treatment · Behavioral: Digital Interventions · Behavioral: Cognitive Processing Therapy (CPT)

  • Active comparator
    Early PE Non-Responsers Switch (Group E)

    Early NON-RESPONDERS to PE will SWITCH to CPT

    Behavioral: Digital Interventions · Behavioral: Cognitive Processing Therapy (CPT) · Behavioral: Prolonged Exposure (PE)

  • Active comparator
    Early PE Non-Responders Modular (Group F)

    Early NON-RESPONDERS to PE will transition to MODULAR PE

    Behavioral: Modular Prolonged Exposure Therapy · Behavioral: Digital Interventions · Behavioral: Prolonged Exposure (PE)

  • Active comparator
    Early PE Responders Continue (Group G)

    Early RESPONDERS will CONTINUE in their PE treatment

    Behavioral: Digital Interventions · Behavioral: Prolonged Exposure (PE)

  • Active comparator
    Early PE Responders Step Down (Group H)

    Early RESPONDERS to PE will STEP DOWN to self-managed PE

    Behavioral: Step Down Treatment · Behavioral: Digital Interventions · Behavioral: Prolonged Exposure (PE)

Interventions

  • BehavioralModular Cognitive Processing Therapy

    CPT is a first-line treatment for PTSD that includes the following core elements: (a) identification of "stuck points" in thinking that interfere with recovery and (b) using Socratic questioning and a series of Contains the same core elements of CPT, but content is repackaged into modules instead of sessions so that clinicians can select and dose treatment elements according to patient need. Modular CPT contains the same core elements of CPT, but content is repackaged into modules instead of sessions so that clinicians can select and dose treatment elements according to patient need.

    Also known as: Modular CPT

  • BehavioralModular Prolonged Exposure Therapy

    PE is a first-line treatment for PTSD that includes the following core elements: (a) in vivo exposure and (b) imaginal exposure to the trauma memory. Modular PE is comprised of the same elements of standard PE, but clinicians select and dose modules (i.e., imaginal exposure, in vivo exposure) based on individual patient need.

    Also known as: Modular PE

  • BehavioralStep Down Treatment

    Self-managed treatment will involve receiving a self-help version of the remaining treatment materials and ongoing use of the intervention companion app (CPT Coach or PE Coach).

    Also known as: Step Down

  • BehavioralDigital Interventions

    The prompt will be a text message delivered through VA-approved technology (e.g., PETALS).

    Also known as: Daily Digital Prompts

  • BehavioralCognitive Processing Therapy (CPT)

    CPT is a first-line treatment for PTSD that includes the following core elements: (a) identification of "stuck points" in thinking that interfere with recovery and (b) using Socratic questioning and a series of progressive worksheets to examine stuck points, develop balanced beliefs, and facilitate the experience of natural emotions.

    Also known as: CPT

  • BehavioralProlonged Exposure (PE)

    PE is a first-line treatment for PTSD that includes the following core elements: (a) in vivo exposure and (b) imaginal exposure to the trauma memory. In imaginal exposure, participants repeatedly, systematically approach their trauma memory and related thoughts and feelings. In in vivo exposure, participants repeatedly, systematically approach objectively safe people, places, objects, and situations that they avoid because these stimuli remind them of their trauma.

    Also known as: PE

06

What researchers measure

Primary outcomes

  1. Posttraumatic Stress Disorder Checklist (PCL-5)

    The PCL-5 is a psychometrically valid measure and commonly used assessment of PTSD symptoms. A total score is calculated by adding up the ratings for each of the 20 items, which range from 0 to 4 (0=Not at all, 4=Extremely). Higher scores reflect more severe symptoms. A score below 31 generally suggests a sub-clinical range, while scores of 31 or above fall within the clinical range, indicating probable PTSD.

    Time frame: 10 weeks, 20 weeks and 9 months

Secondary outcomes

  1. Patient Health Questionnaire-9 (PHQ-9)

    The PHQ-9 score indicates the severity of depressive symptoms. There are 9 items with scores ranging from 0-3 for each. Total scores range from 0 to 27, with higher scores indicating more severe symptoms. A score of 5-9 is considered mild, 10-14 is moderate, 15-19 is moderately severe, and 20-27 is severe. The PHQ-9 score is not a diagnosis, but rather a screening tool to assess depression severity and guide treatment decisions.

    Time frame: Baseline, 10-weeks, 20-weeks, 9-months

  2. Columbia Suicide Severity Rating Scale (C-SSRS)

    The C-SSRS is a standardized measure used to assess suicide risk, primarily through the presence and severity of suicidal ideation and behavior. The screener version of the C-SSRS consists of 2-6 "Yes" or "No" questions. Responses to questions 1 and 2 determine if questions 3, 4, and 5 are asked. A 'Yes' answer to question 2 prompts questions 3, 4, 5, and 6. A 'No' answer to question 2 directs the responder to question 6. Affirmative ("Yes") responses are summed, with each 'Yes' counting as 1 point. This summation provides a score on a scale of 0-6 indicating suicide risk level. 0 = No risk reported (all "No" responses). 1 - 2 = Low risk. 3 - 6 = Moderate to high risk. A "Yes" response to question 3 or 6a indicates moderate risk (potential plan or lifetime engagement in preparatory behavior). A "Yes" response to question 4, 5, or 6b indicates high risk (active plan, possible intent, or recent preparatory behaviors).

    Time frame: Baseline, 10-weeks, 20-weeks, 9-months

  3. Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF)

    The Q-LES-Q-SF contains 16 questions scored on a 5-point Likert scale with values from 1 ("Very Poor") to 5 ("Very Good"). A total score is calculated by summing the first 14 item responses and ranges from 14 to 70; higher scores are associated with greater life satisfaction and enjoyment. The total score is expressed as a percentage based on the maximum total score of the items completed (1-100). The normal range that represents community sample scores is 70-100, and thus scores below 70 are clinically significant. Note, the last two items (items 15 and 16) ask about medication and overall contentment and are stand-alone items; they are not included in the total score.

    Time frame: Baseline, 20-weeks, 9-months

  4. Brief Inventory of Psychosocial Functioning (B-IPF)

    The B-IPF is a 7-item self-report instrument that evaluates PTSD-related psychosocial functional impairment within the last 30 days across seven functional domains (romantic relationships, family relationships, work, friendships and socializing, parenting, education, and self-care). Items on the B-IPF are scored on a Likert scale from 0 (never) to 6 (always). The B-IPF was designed so that respondents complete only temporally relevant items that reflect a domain that they have participated in over the past 30 days (e.g., participants who were not enrolled in school within the past 30 days are instructed to skip the education item). The BIPF is scored by summing the scored items to create a total score, dividing the total score by the maximum possible score based on the number of items scored, and multiplying by 100. Thus, the B-IPF represents an overall index of functioning, with higher scores indicating greater functional impairment

    Time frame: Baseline, 10-weeks, 20-weeks, 9-months

07

Study locations

3 of 4 sites recruiting
  • Augusta VA
    Augusta, Georgia 30904, United States
    Recruiting
  • Ann Arbor VA
    Ann Arbor, Michigan 48105, United States
    Recruiting
  • Battle Creek VA
    Battle Creek, Michigan 49037, United States
    Not yet recruiting
  • Salt Lake City VA
    Salt Lake City, Utah 84148, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07176273
Lead sponsor
The University of Texas Health Science Center at San Antonio
Collaborators
United States Department of Defense
Responsible party
Stefanie LoSavio (Assistant Professor of Psychiatry & Behavioral Sciences, The University of Texas Health Science Center at San Antonio) — Principal investigator
First posted
Sep 16, 2025
Start date
Dec 12, 2025
Primary completion
May 22, 2028 (estimated)
Completion
Aug 14, 2028 (estimated)
Last update
Dec 19, 2025

Study contacts

Stefanie LoSavio, PhD
Contact
losavio@uthscsa.edu
210-562-6700
Rebecca Sripada, PhD
Contact
Rebecca.sripada@va.gov
734-222-7432
Stefanie LoSavio, PhD
principal investigator · The University of Texas Health Science Center at San Antonio
Rebecca Sripada, PhD
principal investigator · VA Ann Arbor-506

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion